Clinical Trials Logo

Filter by:
  • Terminated  
  • Page [1] ·  Next »
NCT ID: NCT05627791 Terminated - Vaginal Atrophy Clinical Trials

Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Start date: November 30, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the quality of life. Topical estrogen is recommended for the treatment of vulvovaginal atrophy in postmenopausal women and the FDA approved it. But it may increase the risk of breast and endometrial cancer. The oxytocin hormone also promotes positive social behavior, stress regulation, and female sexual arousal. Many previous studies show that topical oxytocin is useful for reducing vaginal atrophy in postmenopausal women.

NCT ID: NCT05540665 Terminated - Lupus Nephritis Clinical Trials

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Start date: April 26, 2023
Phase: Phase 2
Study type: Interventional

Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).

NCT ID: NCT05466240 Terminated - Dengue Fever Clinical Trials

Study of AT-752 in Patients With Dengue Infection

Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

NCT ID: NCT05232864 Terminated - Lupus Nephritis Clinical Trials

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Start date: August 22, 2022
Phase: Phase 3
Study type: Interventional

The purpose is to provide treatment with secukinumab delivered subcutaneously (s.c.) via pre-filled syringe (PFS) for participants who complete study treatment until the Week 104 of the core study CAIN457Q12301 and to obtain long term efficacy, safety and tolerability data

NCT ID: NCT05125068 Terminated - IgA Nephropathy Clinical Trials

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

NCT ID: NCT05057897 Terminated - Clinical trials for COVID-19, SARS-CoV-2

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

VICTORIA
Start date: January 31, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.

NCT ID: NCT05056727 Terminated - Clinical trials for Renal Insufficiency, Chronic

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

STABILIZE-CKD
Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate [eGFR] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.

NCT ID: NCT05011513 Terminated - COVID-19 Clinical Trials

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Start date: August 25, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.

NCT ID: NCT04978337 Terminated - Clinical trials for Respiratory Syncytial Virus

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

PRIMROSE
Start date: November 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.

NCT ID: NCT04847232 Terminated - Hyperkalemia Clinical Trials

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Start date: April 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.